|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1523 News |
|
| «12...56789101112131415...3031» |
- Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Enrollment open: A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV (clinicaltrials.gov) - Nov 12, 2014
P1/2, N=100, Recruiting, Sponsor: Mount Sinai Hospital, Canada
Not yet recruiting --> Recruiting
- Enrollment open: Do Some Healthy Adults Consistently Have Systemic Reactions to Influenza Vaccines? (clinicaltrials.gov) - Nov 12, 2014
P4, N=35, Recruiting, Sponsor: Mount Sinai Hospital, Canada
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Flublok Quadrivalent (influenza vaccine) / Sanofi
New P3 trial: Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age (clinicaltrials.gov) - Nov 7, 2014
P3, N=9000, Recruiting, Sponsor: Protein Sciences Corporation
- Trial primary completion date: Testing the AVI-7100 Flu Drug in Healthy Volunteers (clinicaltrials.gov) - Nov 7, 2014
P1, N=150, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2014 --> Dec 2016
- | lenalidomide / Generic mfg.
Enrollment open: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Nov 7, 2014
P2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2014 --> Dec 2016 Withdrawn --> Recruiting
- Clinical: Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts (clinicaltrials.gov) - Nov 6, 2014
P=N/A, N=4000, Not yet recruiting, Sponsor: Columbia University
- Enrollment closed: PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging (clinicaltrials.gov) - Nov 5, 2014
P=N/A, N=165, Active, not recruiting, Sponsor: Columbia University
Withdrawn --> Recruiting Recruiting --> Active, not recruiting
- |||| Trial primary completion date: Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu (clinicaltrials.gov) - Nov 5, 2014
P3, N=244, Recruiting, Sponsor: Novartis
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2014 --> May 2015
- |||| Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) / GSK, Rotarix (rotavirus vaccine) / GSK, Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial primary completion date: Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants (clinicaltrials.gov) - Nov 5, 2014
P3, N=4003, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Jul 2014 --> May 2015 Trial primary completion date: Jul 2013 --> Nov 2011
- oseltamivir / Generic mfg.
New P1 trial: An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study. (clinicaltrials.gov) - Nov 4, 2014
P1, N=100, Not yet recruiting, Sponsor: McMaster University
- Trial completion, Enrollment change: How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice (clinicaltrials.gov) - Nov 4, 2014
P=N/A, N=206703, Completed, Sponsor: NorthShore University HealthSystem
Trial primary completion date: Jul 2013 --> Nov 2011 Recruiting --> Completed | N=15000 --> 206703
- |||| oseltamivir / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza (clinicaltrials.gov) - Nov 3, 2014
P4, N=161, Completed, Sponsor: Materia Medica Holding
Recruiting --> Completed | N=15000 --> 206703 Recruiting --> Completed | N=370 --> 161 | Trial primary completion date: Mar 2015 --> Apr 2014
- Enrollment open: H7N9 Mix and Match With MF59 in Healthy Elderly Persons (clinicaltrials.gov) - Nov 3, 2014
P2, N=600, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=370 --> 161 | Trial primary completion date: Mar 2015 --> Apr 2014 Not yet recruiting --> Recruiting
- |||||| Enrollment open: Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico. (clinicaltrials.gov) - Oct 31, 2014
P3, N=282, Recruiting, Sponsor: Novartis
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Enrollment closed, Trial primary completion date: Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study) (clinicaltrials.gov) - Oct 30, 2014
P2/3, N=405, Active, not recruiting, Sponsor: PT Bio Farma
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Jul 2014
- FluLaval Quadrivalent (influenza vaccine) / GSK
Trial withdrawal: FluLaval® Quadrivalent Pregnancy Registry (clinicaltrials.gov) - Oct 27, 2014
P=N/A, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Jul 2014 Active, not recruiting --> Withdrawn
- ||| Fluzone Quadrivalent (influenza vaccine) / Sanofi
Enrollment closed: A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years (clinicaltrials.gov) - Oct 27, 2014
P4, N=400, Active, not recruiting, Sponsor: bioCSL PTY LTD
Active, not recruiting --> Withdrawn Recruiting --> Active, not recruiting
- lenalidomide / Generic mfg.
Enrollment change, Trial withdrawal: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 24, 2014
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=35 --> 0 | Not yet recruiting --> Withdrawn
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old (clinicaltrials.gov) - Oct 24, 2014
P1, N=24, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Enrollment closed: Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations (clinicaltrials.gov) - Oct 24, 2014
P2, N=400, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=35 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- ||| Fluarix Quadrivalent (influenza vaccine) / GSK
Trial completion: Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - Oct 24, 2014
P1, N=240, Completed, Sponsor: Crucell Holland BV
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Effects of Yoga on Objective and Self-reported Health Indicators Among Female and Male Individuals (clinicaltrials.gov) - Oct 23, 2014
P=N/A, N=44, Completed, Sponsor: Karolinska Institutet
Active, not recruiting --> Completed Recruiting --> Completed | N=90 --> 44 | Trial primary completion date: Jun 2016 --> Oct 2014
- Trial primary completion date: Use of Probiotics to Prevent Influenza (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=1440, Recruiting, Sponsor: McMaster University
Recruiting --> Completed | N=90 --> 44 | Trial primary completion date: Jun 2016 --> Oct 2014 Trial primary completion date: May 2014 --> May 2015
- Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial initiation date, Adverse events: IVVE:Pilot: Influenza Vaccine To Prevent Adverse Vascular Events:Pilot (clinicaltrials.gov) - Oct 22, 2014
P2, N=600, Not yet recruiting, Sponsor: McMaster University
Trial primary completion date: May 2014 --> May 2015 Initiation date: Dec 2013 --> Oct 2014
- ||||| Anflu (trivalent influenza virus split vaccine) / Sinovac
New P4 trial: The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine (clinicaltrials.gov) - Oct 22, 2014
P4, N=182, Completed, Sponsor: Sinovac Biotech Co., Ltd
- |||||| FluLaval Quadrivalent (influenza vaccine) / GSK
Enrollment open: Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age (clinicaltrials.gov) - Oct 20, 2014
P3, N=2400, Recruiting, Sponsor: GlaxoSmithKline
Initiation date: Dec 2013 --> Oct 2014 Not yet recruiting --> Recruiting
- Inactivated Quadrivalent Influenza Vaccine (Split Virion) (influenza vaccine) / Jiangsu Jindike Biotechnology
New P1 trial: A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China (clinicaltrials.gov) - Oct 20, 2014
P1, N=40, Not yet recruiting, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
- ||| Pneumococcal vaccines: System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=30000, Not yet recruiting, Sponsor: University of Massachusetts, Worcester
- ||| Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Enrollment closed: Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults (clinicaltrials.gov) - Oct 17, 2014
P4, N=208, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Trial completion: A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh (clinicaltrials.gov) - Oct 17, 2014
P3, N=1761, Completed, Sponsor: PATH
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P1 trial: Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients (clinicaltrials.gov) - Oct 17, 2014
P1, N=100, Not yet recruiting, Sponsor: Yale University
- New P4 trial: Do Some Healthy Adults Consistently Have Systemic Reactions to Influenza Vaccines? (clinicaltrials.gov) - Oct 15, 2014
P4, N=35, Not yet recruiting, Sponsor: Mount Sinai Hospital, Canada
- | Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P1/2 trial: A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV (clinicaltrials.gov) - Oct 15, 2014
P1/2, N=100, Not yet recruiting, Sponsor: Mount Sinai Hospital, Canada
- |||||| Fluarix Quadrivalent (influenza vaccine) / GSK
Enrollment open: Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older (clinicaltrials.gov) - Oct 15, 2014
P3, N=356, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Trial completion: A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 (clinicaltrials.gov) - Oct 15, 2014
P1, N=280, Completed, Sponsor: Novavax
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial primary completion date: Immune Responses Induced by Different Licensed Influenza Vaccines (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=36, Active, not recruiting, Sponsor: University of Massachusetts, Worcester
Active, not recruiting --> Completed Trial primary completion date: Mar 2014 --> Mar 2015
- ||||| Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P4 trial: Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults (clinicaltrials.gov) - Oct 11, 2014
P4, N=208, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- ||| Flucelvax (influenza virus trivalent vaccine) / CSL Behring
Enrollment open: Flucelvax Pregnancy Registry (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=600, Recruiting, Sponsor: Novartis
Trial primary completion date: Mar 2014 --> Mar 2015 Not yet recruiting --> Recruiting
- |||| Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Enrollment open: Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults (clinicaltrials.gov) - Oct 11, 2014
P4, N=208, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Trial completion: Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older. (clinicaltrials.gov) - Oct 11, 2014
P1, N=627, Completed, Sponsor: Novartis Vaccines
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| HibTITER (diphtheria crm197 protein conjugate) / Nuron Biotech, Mitsubishi Tanabe
Enrollment closed: Exploratory Clinical Study of MT-2301 (clinicaltrials.gov) - Oct 10, 2014
P2, N=150, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Audenz (influenza A (H5N1) monovalent vaccine adjuvanted) / CSL Behring
Enrollment closed: Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions (clinicaltrials.gov) - Oct 10, 2014
P3, N=540, Active, not recruiting, Sponsor: Novartis Vaccines
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring
Enrollment open: Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05 (clinicaltrials.gov) - Oct 10, 2014
P3, N=1400, Recruiting, Sponsor: Novartis
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring
Enrollment open: Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. (clinicaltrials.gov) - Oct 10, 2014
P3, N=10616, Recruiting, Sponsor: Novartis Vaccines
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||| Enrollment closed: Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China (clinicaltrials.gov) - Oct 10, 2014
P4, N=600, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Enrollment open: Home Administration of FluMist by Parents/Caregivers (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=120, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring
New P3 trial: Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05 (clinicaltrials.gov) - Oct 2, 2014
P3, N=1400, Not yet recruiting, Sponsor: Novartis
- |||||||||| New P3 trial: Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico. (clinicaltrials.gov) - Oct 2, 2014
P3, N=282, Not yet recruiting, Sponsor: Novartis
- || Enrollment change: Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine (clinicaltrials.gov) - Sep 28, 2014
P1, N=56, Completed, Sponsor: VaxInnate Corporation
Not yet recruiting --> Recruiting N=104 --> 56
- |||| Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults (clinicaltrials.gov) - Sep 28, 2014
P4, N=208, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
N=104 --> 56 Active, not recruiting --> Completed